Coloplast A/S CLPBY
7.28 USD -0.06 (-0.82%)
As ofNov 19, 2026, 3:20 PM EST
7.28 Day range 7.34
5.64 52-week range 9.29
- YTD
- -14.35%
- 1 year
- -18.02%
News
seekingalpha.com Coloplast: Turnaround Is Underway, But Upside Is Limited Coloplast remains a long-term 'Buy' but with limited short-term upside as shares approach intrinsic value. CLPBF's revised mid-term guidance now targets 5–7% organic growth and EBIT margins in the…
defenseworld.net Contrasting Coloplast A/S (OTCMKTS:CLPBY) & Omnicell (NASDAQ:OMCL) Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and Omnicell (NASDAQ: OMCL - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses…
seekingalpha.com Coloplast A/S (CLPBY) Q4 2026 Earnings Call Transcript Coloplast A/S (CLPBY) Q4 2026 Earnings Call Transcript
reuters.com Coloplast pares back China operations as market recovery remains elusive Coloplast pares back China operations as market recovery remains elusive
defenseworld.net Coloplast A/S (OTCMKTS:CLPBY) Shares Climb 3.9% – Should You Buy? Shares of Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY - Get Free Report) were up 3.9% during trading on Monday. The company traded as high as $6.72 and last traded at $6.71. Approximately 24,521…
seekingalpha.com Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript Coloplast A/S (CLPBY) Q3 2026 Earnings Call Transcript
reuters.com Coloplast expects Kerecis wound-care unit to return to growth in 2027, CFO says Medical equipment maker Coloplast expects its Kerecis wound-care business to return to growth from January 2027 after changes to U.S. Medicare payments caused sales in outpatient settings to fall…
seekingalpha.com Coloplast Might Have Found Its Bottom Coloplast remains a 'Buy,' trading ~20% below intrinsic value despite recent struggles and special charges. Organic growth was 6% in Q2-25/26, but reported results were impacted by a DKK 3 billion…
seekingalpha.com Coloplast: Went 'BUY' A Bit Early Coloplast is rebased to a 20x P/E with a new price target of 490 DKK, reflecting a more realistic valuation post-premiumization. Recent setbacks—the Kerecis acquisition write-down, product recalls,…
seekingalpha.com Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript Coloplast A/S (CLPBY) Q2 2026 Earnings Call Transcript
seekingalpha.com Coloplast A/S (CLPBY) Q4 2026 Guidance Call Transcript Coloplast A/S (CLPBY) Q4 2026 Guidance Call Transcript
defenseworld.net Comparing Coloplast A/S (OTCMKTS:CLPBY) & Bluejay Diagnostics (NASDAQ:BJDX) Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and Bluejay Diagnostics (NASDAQ: BJDX - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two…
seekingalpha.com Coloplast: The Market Is Throwing Away A High-Quality Compounder Coloplast is now a clear Buy, trading nearly 60% below its all-time high and at historically low valuation multiples. CLPBF's wide economic moat, underpinned by patents and high switching costs,…
globenewswire.com Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons.
globenewswire.com Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons Coloplast A/S - Trading in Coloplast shares by board members, executives or associated persons
globenewswire.com Coloplast appoints Gavin Wood as new CEO Announcement no. 3/2026 Inside information Coloplast appoints Gavin Wood as new CEO The Coloplast Board of Directors is pleased to announce the appointment of Gavin Wood as the new President and…
zacks.com CLPBY or PEN: Which Is the Better Value Stock Right Now? Investors with an interest in Medical - Instruments stocks have likely encountered both Coloplast A/S Sponsored ADR (CLPBY) and Penumbra (PEN). But which of these two stocks offers value investors a…
defenseworld.net Reviewing OPKO Health (NASDAQ:OPK) and Coloplast A/S (OTCMKTS:CLPBY) Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based…
globenewswire.com Coloplast A/S - Updated Financial Calendar 2025-26 Please see enclosed pdf. Update to Financial Calendar Dates Coloplast has updated the dates in its financial calendar for the publication of the FY Financial Statements 2025/26 and the Annual General…
defenseworld.net Coloplast A/S (OTCMKTS:CLPBY) Shares Gap Down – What’s Next? Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY - Get Free Report)'s share price gapped down prior to trading on Friday. The stock had previously closed at $8.38, but opened at $7.83. Coloplast A/S shares…
